Fig. 1

Sitravatinib exerts potent anti-tumor activities against FLT3-ITD AML cell lines. A The IC50 values of each drug for FLT3-WT (THP1, HL60, U937, OCI-AML2, OCI-AML3) or FLT3-ITD (MV4-11 and MOLM13) AML cell lines. Data are mean ± standard error from three independent experiments. B The percentage of cells in different cell cycle phases after 24-h treatment with various concentrations of sitravatinib (S) or gilteritinib (G). Error bars indicate mean ± standard error, n = 3 independent experiments for each cell line. C Apoptotic cell populations of MV4-11 and MOLM13 cell lines after 48-h treatment with sitravatinib (S) or gilteritinib (G). Error bars indicate mean ± standard error, n = 3 independent experiments for each cell line. ***P < 0.001, ****P < 0.0001. D Western blot analysis of PARP1, caspase 8, cleaved-PARP1 (C-PARP1) and cleaved-caspase8 (C-caspase8) expression in MV4–11 and MOLM13 cells after treatment with different doses of sitravatinib for 48 h. E Western blot analysis of p-FLT3, p-STAT5, p-AKT and p-ERK 1/2 in MV4-11 and MOLM13 cells after treatment with sitravatinib at the indicated doses for 4 h